

# amfAR

MAKING AIDS HISTORY



# 2015 Annual Report

amfAR, The Foundation for AIDS Research

# Contents

<b>amfAR in 2015</b>	01
<hr/>	
<b>Grants, Fellowships, and Awards</b>	07
Research Grants, Fellowships and Awards	
TREAT Asia Grants and Awards	
GMT Initiative Awards	
Public Policy Awards	
<hr/>	
<b>Financial Highlights</b>	13
<hr/>	
<b>Leadership and Advisory Committees</b>	15
Board of Trustees	
Scientific Advisory Committee	
Program Advisory Council	
Management Group	

**amfAR, The Foundation for AIDS Research,  
is dedicated to ending the global AIDS  
epidemic through innovative research.**

# amfAR in 2015

## Research


### Countdown to a Cure for AIDS

In February 2015, amfAR launched a \$100 million investment strategy to support its Countdown to a Cure for AIDS initiative, aimed at developing the scientific basis of a cure by 2020. The strategy represents an unprecedented expansion of amfAR's research grant making. Structured to provide sustained support for a wide range of studies that advance both emerging and established ideas, the strategy comprises the following key components:

- ▶ The amfAR Institute for HIV Cure Research, launched at the end of 2015 at the University of California, San Francisco, will be the cornerstone of amfAR's cure research efforts and will be supported by a \$20 million grant over five years.
- ▶ Innovation Grants of up to \$200,000 each will enable researchers to test innovative ideas supported by limited preliminary data. The first round of 11 Innovation Grants totaling close to \$2 million was awarded in February 2015.
- ▶ Impact Grants support the in-depth development of concepts already underpinned by preliminary data showing genuine potential for achieving a cure. In July, amfAR awarded the

first three Impact Grants of \$2 million each over four years. Researchers in Boston, San Francisco, and Melbourne, Australia, are investigating the ability of combinations of antibodies to kill latently infected cells, pursuing a novel intervention aimed at restoring normal immune function in people with HIV, and exploring whether drugs that block so-called immune checkpoints that have proven effective in treating cancer can also be effective against HIV.

- ▶ Investment Grants are aimed at recruiting the experience and expertise of scientists from outside the field of HIV. These \$1 million grants will be awarded over a four-year period. Grantees may have expertise in fields such as cancer, neuroscience, or inflammatory disease that can directly inform efforts to cure HIV.
- ▶ ARCHE—the amfAR Research Consortium on HIV Eradication—supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies. In February 2015, amfAR awarded \$1.5 million to three teams of researchers in the U.S., Denmark, and Germany who are testing the ability of the cancer drug Romidepsin, which has been shown to be effective at “shocking” HIV out of hiding, combined with an antibody to eliminate infected cells and thus reduce the size of the persistent HIV reservoir.



amfAR grantee Dr. Marta Massanella of the University of California, San Diego, is studying a recently discovered subset of CD4 T cells believed to contribute heavily to the latent HIV reservoir.

### Mathilde Krim Fellowships

In October 2014, amfAR awarded an eighth round of Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results.

### Published Research

Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, 44 scientific publications resulted from amfAR-funded research.

### HIV Cure Summit

In November 2014, amfAR held its first annual HIV Cure Summit at the New York Academy of Sciences, where leading amfAR-funded HIV cure researchers reported on their progress and discussed the scientific challenges that continue to stand in the way of a cure. Topics included attempts to eliminate viral reservoirs with methods including “shock and kill,” which involves reactivating the virus so it can be destroyed; vaccines and other immune-based strategies; and gene and cell therapy.



(Left to right) Panel moderator Dr. Jeffrey Laurence with Drs. Eric Arts of Western University, London, Ontario, Jerome Zack of UCLA, and Lars Østergaard of Aarhus University Hospital, Denmark, at amfAR's first annual HIV Cure Summit.

### Think Tank

In March 2015, 12 leading pediatric HIV researchers, immunologists, and other scientists came together in Las Vegas, Nevada, for a second amfAR think tank to discuss progress in the search for a cure for children living with HIV. Participants sought to collectively identify new avenues of investigation that can best build upon recent breakthroughs.

### TREAT Asia

amfAR's TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV treatments to adults and children across the Asia-Pacific through research, education, and advocacy of evidence-based HIV-related policies. The TREAT Asia Network encompasses 20 adult and 18 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists published 28 publications in peer-reviewed medical journals in fiscal year 2015.

### Gathering Critical Information

TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from approximately 9,000 patients at 21 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs and helps define treatment standards specific to HIV/AIDS in Asia. In 2015, TREAT Asia launched a new database called TAHOD-Lite that includes more basic data but from a much larger proportion of the HIV-positive patients seen at participating sites.

### A Global Collaboration

TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. TREAT Asia is working with the Thai Red Cross AIDS Research Centre in Bangkok to conduct a Thai component of a new study that aims to develop and validate a standardized tool to better understand treatment adherence among young people.

### Improving Care for Children

TREAT Asia's Pediatric Network includes 18 sites in six countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database was modeled on the adult database and includes data from approximately 5,500 pediatric patients.



## Adolescent Research

In 2015, TREAT Asia conducted several studies aimed at improving the health and well-being of adolescents living with HIV. Among them was a Thai study, supported by ViiV Healthcare, of whether technology-based interventions can increase adherence to antiretroviral therapy among adolescents.

## Expanding Pre-Exposure Prophylaxis (PrEP) in Thailand

In an effort to improve national HIV prevention efforts, the Thai Red Cross AIDS Research Centre, a TREAT Asia network member, and Adam's Love, Thailand's leading Internet and social media-based HIV outreach initiative, began working on two groundbreaking efforts to bring oral PrEP to men who have sex with men (MSM) in Thailand. Both projects are supported in part by TREAT Asia.

## Exploring Links Between HIV and Cancer

Because MSM living with HIV are twice as likely as those without HIV to develop the anal cancer associated with human papilloma virus (HPV) infection, the Anonymous Clinic of the Thai Red Cross AIDS Research Centre started screening its patients for anal precancers. With amfAR funding, it purchased the high-resolution microscope necessary to diagnose and treat precancerous anal lesions. With support from TREAT Asia and others, three TREAT Asia sites in Indonesia and Malaysia have established similar programs.

## Mobilizing HIV-Positive Youth

With support from ViiV Healthcare's new Positive Action for Adolescents program, TREAT Asia launched a program called

Youth ACATA (Asia Community for AIDS Treatment and Advocacy) in an effort to mobilize HIV-positive youth across the region. It held three Youth ACATA workshops for young people living with HIV from Cambodia, Indonesia, Thailand, and Vietnam.

## Targeting At-Risk Populations Online

In August 2015, Adam's Love (see Expanding Pre-Exposure Prophylaxis [PrEP] in Thailand) launched Adam's Love Taiwan, its fourth country-specific HIV outreach campaign targeting at-risk populations through its unique online edutainment approach that combines educational HIV resources with videos and social media posts from celebrities. Adam's Love is supported by ViiV and amfAR, and sponsored by the Thai Red Cross AIDS Research Centre.

## Education and Advocacy

TREAT Asia continued to publish lay-language articles on AIDS research, policy, and community issues facing the Asia-Pacific region. The articles and educational pieces appear in the *TREAT Asia Report*, a bimonthly e-newsletter, and on TREAT Asia's website, [www.treatasia.org](http://www.treatasia.org). TREAT Asia also published a policy brief urging governments, public health authorities, healthcare providers, and civil society in Asia to address persistent gaps in women's access to reproductive health services, especially for women living with HIV.

## Public Policy

Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation works to secure necessary increases



TREAT Asia consultant Jennifer Ho with two Youth ACATA participants at a workshop in Bangkok

in funding for HIV/AIDS research; implement the U.S. National HIV/AIDS Strategy; expand access to care and treatment; improve prevention; and protect the civil rights of all people affected by HIV/AIDS.

## PEPFAR and the Global Epidemic

PEPFAR—the U.S. President’s Emergency Plan for AIDS Relief—is the largest international program responding to the global HIV/AIDS epidemic and the largest commitment one nation has ever made to combat a disease internationally. In 2015, amfAR launched its PEPFAR Country/Regional Operational Plan database, a comprehensive, navigable database of PEPFAR’s planned funding of HIV/AIDS activities from 2007 to 2014. The database is designed to help civil society organizations, ministries of health and finance, researchers, and other stakeholders to access and understand PEPFAR’s programs and priorities at a deeper level than was possible using other platforms.

## Addressing HIV/AIDS Among Women

In March 2015, amfAR held a Congressional briefing in Washington, D.C., to illuminate the work that remains to be done to achieve an AIDS-free generation among women and girls in the U.S. and globally. The briefing drew leaders from government, academia, and the nonprofit sector, including House Democratic Leader Nancy Pelosi, Jeannette Kagame, First Lady of Rwanda and cofounder of the Organization of African First Ladies Against HIV/AIDS, and Ambassador Deborah Bix, M.D., U.S. Global AIDS Coordinator.

## Shaping the Domestic Response to HIV/AIDS

In July 2015, amfAR issued a report titled *Bolstering State Efforts to Implement the National HIV/AIDS Strategy: Key Indicators and Recommendations for Policymakers and Community Stakeholders*. The report outlined recommendations for how states across the U.S. can improve their HIV prevention and care responses. It was released to coincide with the White House’s 2015 update to the U.S. National HIV/AIDS Strategy.

## HIV and Black Gay Men

In February 2015, amfAR published an issue brief showing that efforts to address the HIV epidemic among black gay men have been consistently inadequate and that immediate steps must be taken to reduce new HIV infections among this underserved population. The brief, titled *HIV and the Black Community: Do #Black (Gay) Lives Matter?* described the underlying factors contributing to elevated infection rates among black men and provided a list of steps that can be taken to mitigate this persistent racial disparity.

## HIV and Injecting Drug Use

A dramatic spike in HIV infections in rural Scott County, Indiana, caused by the sharing of contaminated needles by injecting drug users, underscored the urgent need to expand access to



(Left to right) Her Excellency Jeannette Kagame, First Lady of Rwanda; Dr. Susan Blumenthal, amfAR Senior Policy and Medical Advisor; and Ambassador Deborah Bix, M.D., U.S. Global AIDS Coordinator at an amfAR-sponsored Congressional briefing. (Photo: amfAR)

harm reduction programs and syringe exchange in particular. This mode of transmission continues to be a driver of the epidemic in many parts of the world and amfAR has long played a leading role in advocating the use of federal funds to support these lifesaving HIV prevention programs. In the wake of the Indiana outbreak, amfAR CEO Kevin Robert Frost authored an op-ed on the issue for CNN.com and amfAR published a pair of issue briefs outlining the importance of syringe services programs (SSPs) as a highly effective tool in the fight against the spread of HIV and hepatitis C.

In its *Harm Reduction and the Global HIV Epidemic* report, released in September 2015, amfAR assessed the state of harm reduction worldwide by focusing on the steps that five sample countries—Kenya, Kyrgyzstan, Nigeria, Ukraine, and Vietnam—have, or have not, taken to address the epidemic among people who inject drugs.

## Treatment Access

In a policy brief on hepatitis C and drug pricing, amfAR called for structural changes that alter the pricing incentives for pharmaceutical companies in such a way that they cannot charge extortionate prices for their products, however effective they may be. New pharmaceutical breakthroughs have made curing hepatitis C infection easier and more effective, but they have been priced at aggressively high rates that bear no relation to the cost of research and development.

In another issue brief titled *Trans-Pacific Partnership: Curbing Access to Medicines Now and in the Future*, amfAR strongly opposed the proposed terms of the Trans-Pacific Partnership, warning that expanding existing intellectual property protections could result in a decline in generic competition and an increase in drug costs, while setting an unacceptable precedent for future free trade agreements. Two agreements being negotiated threaten the future availability of affordable generic medicines for diseases such as HIV/AIDS, cancer, tuberculosis, and hepatitis C, and could undermine the global health response in developing countries.

## The GMT Initiative

In every corner of the world, gay men, other men who have sex with men, and transgender individuals (collectively, GMT) are disproportionately affected by HIV. Since 2007, amfAR has been advancing efforts to improve prevention for this population, expand access to testing and treatment, and combat stigma and discrimination in hard-hit countries worldwide.

## Implementation Science Awards

In 2015, the focus of amfAR's grant making through the GMT Initiative evolved from the distribution of small grants to community-based organizations to the support of larger implementation science projects aimed at identifying barriers to HIV testing, treatment and care, and studying the impact of innovative HIV service delivery models for GMT in low- and middle-income countries. amfAR awarded \$2.6 million over three years to support three such studies.



The 2015 amfAR HIV Scholars (left to right): Sheryar Kazar, associated with the Naz Male Health Alliance, Pakistan; Liesl Theron, a consultant supported by Gender Dynamix, South Africa; Erika Castellanos from the Collaborative Network of Persons Living with HIV (C-NET+), Belize; and Weibin Cheng from the Chinese Center for Disease Control and Prevention and GZTZ.org.

- ▶ Dr. Chris Beyrer of Johns Hopkins University is leading a team of researchers and community-based services (in collaboration with the International HIV/AIDS Alliance Myanmar) in evaluating the effectiveness of promising interventions for GMT in Myanmar, where increased HIV testing and treatment opportunities are becoming available. The researchers are assessing the effectiveness of HIV self-testing, point-of-care CD4 testing, and the use of “peer navigators” familiar with the local health system to help those newly diagnosed gain access to treatment and care.
- ▶ In Lima, Peru, Dr. Javier Lama of Asociación Civil Impacta Salud y Educación and his team aim to improve the continuum of care among transgender women by using an innovative model that integrates HIV prevention and treatment services with transgender-affirming medical care.
- ▶ And in Bangkok, Thailand, Dr. Nittaya Phanuphak and her team at the Thai Red Cross AIDS Research Centre aim to show how innovative technologies such as GMT-targeted websites using online counseling and support can be utilized to increase rates of HIV testing and referrals to prevention and treatment programs.

## Evidence in Action

In 2015, amfAR supported five community-based organizations in Africa and Latin America in evaluating their efforts to improve HIV treatment and care among GMT individuals as part of the GMT Initiative's Evidence in Action Program, which evaluates the impact of community-based programs with the ultimate goal of implementing the most workable strategies for stopping the spread of HIV/AIDS. Evidence in Action was developed with support from ViiV Healthcare's Positive Action program and the Elton John AIDS Foundation.

## Supporting Young Researchers

amfAR also supported four young researchers from Belize, China, Pakistan, and South Africa undergoing five months of graduate-level public health study at the Center for LGBT Health Research of the Graduate School of Public Health at the University of Pittsburgh. This amfAR HIV Scholars Program aims to strengthen GMT community-based research and responses to HIV, often in areas where little data about HIV among GMT currently exist and where stigma and discrimination deter many GMT from seeking HIV testing and services.

## Opposites Attract

In January 2015, amfAR provided support to the Instituto Pesquisa Clinica Evandro Chagas in Rio de Janeiro, Brazil, one of 16 clinical sites participating in the Opposites Attract Study, an ongoing international study that explores the effectiveness of “treatment as prevention” in gay male serodiscordant relationships (one sexual partner is living with HIV and the other is not). The study aims to determine the extent to which HIV incidence is associated with whether an HIV-positive partner is on antiretroviral therapy.

## Lessons from the Front Lines

With support from the Arcus Foundation and in collaboration with Global Action for Trans Equality (GATE), amfAR published *Lessons From the Front Lines: Trans Health and Rights*. The report examined data on access to health services and legal protections for transgender individuals in different settings and detailed how stigma and discrimination combine to create nearly insurmountable challenges for these populations and the organizations that serve them.

## Public Information

Through a wide range of communications vehicles and platforms, amfAR disseminates information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences. Through these activities, the Foundation increases awareness of the persistent global public health threat posed by HIV/AIDS and works to combat the stigma associated with HIV that deters many people from getting tested or seeking treatment.

## Informing and Educating

amfAR publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. Publications include *Innovations*, a newsletter published twice a year and distributed to more than 45,000 people, and a monthly e-mail newsletter distributed to nearly 100,000. Featuring news, interviews, and other original content, the Foundation's website—www.amfar.org— attracts an average 30,000 visitors per month.

## Social Media

amfAR vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly added content to its Facebook page and live-tweeted and posted images on Instagram from fundraising and program events. amfAR has 67,000 likes on Facebook, 35,400 Twitter followers, and more than 81,000 Instagram followers.

## Media Outreach

amfAR works closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS-related press coverage. Articles and reports involving amfAR—many of which included interviews with amfAR staff and spokespeople—were carried in numerous media outlets, including the *New York Times*, the *Wall Street Journal*, the *Washington Post*, and the *Huffington Post*, and news agencies such as The Associated Press, CNN, Bloomberg News, and Reuters.

## Enlisting the Help of Public Figures

amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support from prominent public figures began with the late Dame Elizabeth Taylor, amfAR's Founding International Chairman, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Campaign Chair Sharon Stone.

Other celebrity supporters included Andrea Bocelli, Adrien Brody, Naomi Campbell, Dean and Dan Caten, Cher, Andy Cohen, Anderson Cooper, Laverne Cox, Miley Cyrus, Rosario Dawson, Leonardo DiCaprio, Whoopi Goldberg, Iman, Scarlett Johansson, amfAR Ambassador Milla Jovovich, Harvey Keitel, Heidi Klum, Eva Longoria, Lea Michele, Kylie Minogue, Kate Moss, Ryan Murphy, Gwyneth Paltrow, Eddie Redmayne, Rihanna, Michelle Rodriguez, Chris Rock, Carine Roitfeld, Brooke Shields, Mario Testino, Robin Thicke, Justin Timberlake, Chris Tucker, Dita Von Teese, Harvey Weinstein, and amfAR Ambassador Michelle Yeoh.





## 2015 RESEARCH GRANTS, FELLOWSHIPS AND AWARDS

All projects listed below were awarded funding during the period October 1, 2014, through September 30, 2015

<sup>1</sup>Supported in part with funds provided by the FAIR Foundation

### amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

#### Combining romidepsin and 3BNC117 to deplete the HIV-1 reservoir

Principal Investigator:  
Michel Nussenzweig, MD, PhD  
The Rockefeller University, New York, NY  
Co-Investigators:  
Ole Schmeltz Søgaard, MD, PhD  
Aarhus University Hospital, Aarhus, Denmark  
Gerd Fätkenheuer, MD  
University Hospital of Cologne, Cologne, Germany  
\$1,500,000

### INNOVATION GRANTS

#### Broadly Neutralizing Antibodies for HIV-1 Remission and Eradication

Principal Investigator: Dan Barouch, MD, PhD  
Beth Israel Deaconess Medical Center  
Boston, MA  
\$1,991,958

#### Impact of Sirolimus (Rapamycin) on HIV-1 Persistence and Immune Function

Principal Investigator: Timothy Henrich, MD  
Regents of the University of California,  
San Francisco  
San Francisco, CA  
\$2,000,000

#### Combination immune checkpoint blocker inhibition to eliminate HIV latency

Principal Investigator: Sharon Lewin, FRACP, PhD  
University of Melbourne  
Melbourne, Australia  
\$1,999,740

### INNOVATION GRANTS

#### Epigenetic mechanisms of HIV transcriptional activation

Principal Investigator: Karol Bomsztyk, MD  
University of Washington  
Seattle, WA  
\$180,000

#### Creation of transgenic CCR5 knockout Mauritian cynomolgus macaques

Principal Investigator: Benjamin Burwitz, PhD  
Oregon Health and Science University  
Portland, OR  
\$179,824<sup>1</sup>

#### Combining CTL with TLR-2 Agonists to Eradicate Natural HIV Reservoirs

*Funded with support from generationCURE*  
Principal Investigator: Brad Jones, PhD  
The George Washington University  
Washington, DC  
\$179,985

#### The size and maintenance of the latent HIV reservoir in T-cell subsets

Principal Investigator: Marta Massanella, PhD  
Veterans Medical Research Foundation  
San Diego, CA  
*Transferred to Université de Montréal,  
Montreal, Canada*  
\$180,000<sup>1</sup>

#### Interleukin-21 therapy to reduce HIV persistence

Principal Investigator: Mirko Paiardini, PhD  
Emory University  
Atlanta, GA  
\$179,999<sup>1</sup>

#### Cell-Intrinsic Immune Modulation of HIV Latency

Principal Investigator: Satish Pillai, PhD  
Blood Systems, Inc.  
San Francisco, CA  
\$180,000<sup>1</sup>

#### Molecular characterization of non-induced proviruses

Principal Investigator: Vicente Planelles, PhD  
University of Utah  
Salt Lake City, UT  
\$180,000<sup>1</sup>

#### Understanding the role of the HIV Envelope in viral persistence and latency

Principal Investigator: Michael Roche, PhD  
Peter Doherty Institute  
Melbourne, Australia  
\$141,719

#### Shaping Innate/Adaptive Immune Effector Functions By TLR9 agonist Immunotherapy

Principal Investigator:  
Ole Schmeltz Søgaard, MD, PhD  
Aarhus University Hospital  
Aarhus, Denmark  
\$179,944<sup>1</sup>

#### Impact of everolimus on HIV persistence post kidney or liver transplant

An Innovation Grant in Memory of Alberto Diaz  
Principal Investigator: Peter Stock, MD, PhD  
Regents of the University of California, San Francisco  
San Francisco, CA  
\$180,000

#### CNS as Reservoir for Subtype C HIV-1 Infection

Principal Investigator: Charles Wood, PhD  
University of Nebraska-Lincoln  
Lincoln, NE  
\$180,000

### MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCH

#### Fc effector activity of anti-HIV-1 broadly neutralizing antibodies

Principal Investigator: Stylianos Bournazos, PhD  
The Rockefeller University  
New York, NY  
\$150,000

#### Activation of the inflammasome by HIV-1

Principal Investigator: Henning Hofmann, PhD  
New York University  
New York, NY  
\$150,000

#### Decoding the Vpx/Vpr system

Principal Investigator: David Schwefel, DSc  
MRC National Institute for Medical Research  
London, United Kingdom  
\$149,600

#### A3G induced viral evolution

Principal Investigator: Spyridon Stavrou, PhD  
Trustees of the University of Pennsylvania  
Philadelphia, PA  
\$150,000

### PHASE II KRIM FELLOWSHIP GRANTS

#### Host factors that protect humans and great apes against lentiviruses

Principal Investigator: Lucie Etienne, PhD  
Institut National de la Santé et de la Recherche Médicale, INSERM  
Bron, France  
\$60,000

#### Regulation of Env-specific germinal center B cells

Principal Investigator: Mattias Forsell, PhD  
Umeå University  
Umeå, Sweden  
\$56,171

#### Regulation of the conformational transitions in HIV-1 envelope glycoprotein

Principal Investigator: Alon Herschhorn, PhD  
Dana-Farber Cancer Institute  
Boston, MA  
\$51,649

### SCIENTIFIC MEETINGS

#### HIV-1 and How to Kill a Killer: Attempts at Total Functional Cure of HIV-1

Principal Investigator: Jan Witkowski, PhD  
Cold Spring Harbor Laboratory  
Cold Spring Harbor, NY  
\$12,000

#### Conference on Cell & Gene Therapy for HIV Cure (2015)

Principal Investigator: Keith Jerome, MD, PhD  
Fred Hutchinson Cancer Research Center  
Seattle, WA USA  
\$5,000

## 2015 TREAT ASIA GRANTS AND AWARDS

<sup>1</sup>Supported by National Institutes of Health cooperative agreement number U01AI069907 with funds from the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Cancer Institute

<sup>2</sup>Supported by National Institutes of Health grant number R01HD073972 funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

<sup>3</sup>Supported with funds provided by the AIDS Life Association

<sup>4</sup>Supported with funds provided by the Open Society Foundations

<sup>5</sup>Supported with funds provided by Viiv Healthcare

<sup>6</sup>Supported with funds provided by the Mel Wolf Foundation

### AUSTRALIA

#### AUSTRALIA HIV OBSERVATIONAL DATABASE (AHOD) SITES

**O'Brien Street Practice**  
Adelaide, South Australia  
William Donohue, MBBS  
\$1,500

**Sexual Health and HIV Service In Metro North**  
Brisbane, Queensland  
Diane Rowling, MBBS, MTH, F(PHM), RACP, FACHSHM  
\$4,650<sup>1</sup>

**Cairns Sexual Health Service**  
Cairns, Queensland  
Darren Russell, MD  
\$4,950<sup>1</sup>

**RPA Sexual Health Clinic**  
Camperdown, New South Wales  
David Templeton, PhD  
\$675

**Monash Health - Clayton**  
Clayton, Victoria  
Ian Woolley, MBBS, FRACP  
\$3,900

**D.A. Ellis Pty., Ltd.**  
Coffs Harbour, New South Wales  
David Ellis, MBBS  
\$975

**East Sydney Doctors**  
Darlinghurst, New South Wales  
David Baker, BHB  
\$7,050<sup>1</sup>

**Holdsworth House Medical Practice**  
Darlinghurst, New South Wales  
Mark Bloch, MD  
\$6,000<sup>1</sup>

**St. Vincent's Hospital Sydney**  
Darlinghurst, New South Wales  
David A. Cooper, MD  
\$5,250<sup>1</sup>

**Taylor Square Private Clinic**  
Darlinghurst, New South Wales  
Robert Finlayson, MBBS  
\$5,250<sup>1</sup>

**Northern Territory Dept of Health & Community Services, Sexual Health & Blood Borne Virus Program**  
Darwin, Northern Territory  
Manoji Gunathilake, MD, MBBS, DFRSH  
\$900

**Gladstone Road Medical Centre**  
Highgate Hill, Queensland  
David Orth, MBBS, DIP Ven  
\$5,400<sup>1</sup>

**Nepean Blue Mountains Local Health District, Blue Mountains Sexual Health and HIV Clinic**  
Katoomba, New South Wales  
Eva Jackson, MBBS, FACHSHM  
\$1,050

**Nepean Blue Mountains Local Health District, Nepean Sexual Health Clinic**  
Kingswood, New South Wales  
Eva Jackson, MBBS, FACHSHM  
\$750

**Sexual Health and AIDS Services (SHAIDS)**  
Lismore, New South Wales  
David Smith, MBBS, DipVen, FACHSHM, GrapDip BA  
\$5,850<sup>1</sup>

**Melbourne Sexual Health Centre**  
Clayton, Victoria  
Tim Read, MBBS, DipVen, FRACGP, FACHSHM, EpiDip  
\$4,650<sup>1</sup>

**Victorian HIV Service, Infectious Diseases Department, The Alfred Hospital**  
Melbourne, Victoria  
Jennifer Hoy, MBBS  
\$5,925<sup>1</sup>

**Sunshine Coast Hospital and Health Service**  
Nambour West, Queensland  
David Sowden, MBBS  
\$6,750<sup>1</sup>

**Northside Clinic (Vic) Pty Ltd**  
North Fitzroy, Victoria  
Richard Moore, MBBS, FRACGP, DipOb, DipVen  
\$7,500<sup>1</sup>

**Royal Perth Hospital**  
Perth, Western Australia  
David Nolan, MBBS, FRACP, PhD  
\$5,250<sup>1</sup>

**Prahran Market Clinic Pty Ltd**  
Prahran, Victoria  
Norman Roth, MBBS FACHSHM  
\$5,925<sup>1</sup>

**Sydney Sexual Health Centre, Sydney Hospital**  
Sydney, New South Wales  
Caroline Thng, MBBS, MRCP  
\$4,500<sup>1</sup>

**Hunter New England Health, Clinic 468, Tamworth Sexual Health Service**  
Tamworth NEMSC, New South Wales  
Nathan Ryder, MD  
\$900

**Illawarra Shoalhaven Local Health District**  
Warrawong, New South Wales  
Katherine Brown, MD  
\$1,350

**University of New South Wales**  
Sydney, New South Wales  
Matthew G. Law, PhD

Asia-Pacific HIV Research Collaboration: TREAT Asia HIV Observational Database and Australia HIV Observational Database  
\$361,314<sup>1</sup>

Asia-Pacific HIV Research Collaboration: Cancer Studies  
\$60,686<sup>1</sup>

Asia-Pacific HIV Research Collaboration: TREAT Asia Pediatric HIV Observational Database  
\$182,262<sup>1</sup>

### CAMBODIA

**National Center for HIV/AIDS, Dermatology & STDS / Cambodia National Institute of Public Health**  
Phnom Penh  
Ly Penh Sun, MD, MSc  
TREAT Asia HIV Observational Database (TAHOD)  
\$20,000<sup>1</sup>

TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$25,000<sup>3</sup>

**National Pediatric Hospital**  
Phnom Penh  
Ung Vibol, MD  
Training for early disclosure for children and adolescents in National Pediatric Hospital  
\$10,000<sup>3</sup>

**New Hope for Cambodian Children**  
Killeen, TX  
John Tucker  
Our Village  
\$50,000

### CHINA

**Beijing Ditan Hospital**  
Beijing  
Fujie Zhang, MD  
TREAT Asia HIV Observational Database (TAHOD)  
\$16,000<sup>1</sup>

**Queen Elizabeth Hospital**  
Hong Kong  
Man Po Lee, MBBS  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,660<sup>1</sup>

### INDIA

**Johns Hopkins University at B.J. Medical College and Sassoon General Hospital**  
Pune  
Vidya Mave, MD, MPH  
Epidemiology of HIV/AIDS and associated comorbidities in a public antiretroviral treatment (ART) clinic in Pune, India  
\$304,185<sup>1</sup>

**Chennai Antiviral Research and Treatment Clinical Research Site, YRG CARE Medical Centre, VHS**  
Chennai  
Naglingeswaran Kumarasamy, MBBS, PhD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,860<sup>1</sup>

TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

#### **Institute of Infectious Diseases**

Pune  
Sanjay Pujari, MD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,040<sup>1</sup>

#### **Wide Angle Social Development Organization**

Imphal  
Rajkumar Nalinikanta  
Improving Access to HCV treatment in Manipur Phase III  
\$8,087<sup>4</sup>

Extension of support “Improving Access to HCV treatment” Phase II  
\$3,508<sup>4</sup>

### **INDONESIA**

#### **Cipto Mangunkusumo General Hospital**

Jakarta  
Nia Kurniati, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

Bone health and vitamin D status among perinatally HIV-infected Asian children with virological suppression  
\$13,065<sup>5</sup>

Evy Yuniastuti, MD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,750<sup>1</sup>

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment  
\$35,897

#### **Indonesia AIDS Coalition**

Jakarta  
Aditya Wardhana  
Creating joint action plans to address the needs of Children Living with HIV  
\$9,047<sup>5</sup>

#### **Sanglah Hospital, Udayana University School of Medicine**

Denpasar, Bali  
Tuti Parwati Merati, MD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,00<sup>1</sup>

#### **Sanglah Hospital, Udayana University School of Medicine**

Denpasar, Bali  
Ketut Dewi Kumara Wati, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

#### **Spiritia Foundation**

Jakarta  
Meirinda Sebayang  
Indonesia pediatric HIV program assessment  
\$9,986<sup>5</sup>

Promoting adherence and nutritional care for Children with HIV  
\$12,776<sup>3</sup>

#### **Yayasan Bali Peduli**

Gianyar, Bali  
Steve Wignall  
HIV Outreach/Education and Prevention for Youth, Women and Children in Gianyar, Bali  
\$12,000<sup>6</sup>

### **JAPAN**

#### **National Center for Global Health and Medicine**

Tokyo  
Shinichi Oka, MD  
TREAT Asia HIV Observational Database (TAHOD)  
\$16,000<sup>1</sup>

### **MALAYSIA**

#### **Hospital Likas**

Kota Kinabalu  
Fong Siew Moy, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI  
\$2,200<sup>1</sup>

#### **Hospital Raja Perempuan Zainab II**

Kota Bharu  
Nik Khairulddin Nik Yusoff, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI  
\$2,300<sup>1</sup>

#### **Pediatric Institute, Hospital Kuala Lumpur**

Kuala Lumpur  
Kamarul Azahar Mohd Razali, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$7,500<sup>3</sup>

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI  
\$4,200<sup>1</sup>

#### **Penang Hospital**

Georgetown  
Revathy Nallusamy, MBBS  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$2,500<sup>3</sup>

#### **Sungai Buloh Hospital**

Sungai Buloh  
Benedict Lim Heng Sim, MBBS, MRCP  
TREAT Asia HIV Observational Database (TAHOD)  
\$15,000<sup>1</sup>

#### **University of Malaya**

Kuala Lumpur  
Adeeba Kamarulzaman, MBBS, FRACP, FAMM, FASc  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,000<sup>1</sup>

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment  
\$20,195

### **PHILIPPINES**

#### **Asian Foundation for Tropical Medicine, Inc.**

Muntinlupa City  
Rossana Ditungco, MD  
National HIV Testing Week Campaign and International AIDS Candlelight Memorial, Philippines  
\$3,351

TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,410<sup>1</sup>

### **SINGAPORE**

#### **Tan Tock Seng Hospital**

Singapore  
Oon Tek Ng, MBBS, MRC  
TREAT Asia HIV Observational Database (TAHOD)  
\$16,000<sup>1</sup>

### **SOUTH KOREA**

#### **Yonsei University College of Medicine**

Seoul  
Jun Yong Choi, MD, PhD  
TAHOD Low-Intensity Transfer (TAHOD LITE)  
\$5,000<sup>1</sup>

TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$18,690<sup>1</sup>

### **TAIWAN**

#### **Taipei Veterans General Hospital**

Taipei City  
Wing-Wai Wong, MD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$24,590<sup>1</sup>

#### **Kaohsiung Medical University**

Kaohsiung  
Yi-Ming Chen, MD, ScD  
Using the Taiwan National Health Insurance Database to Study the Associations between Chronic Illnesses & Cancer in PLHA  
\$39,397<sup>1</sup>

### **THAILAND**

#### **Chiang Mai University - Research Institute for Health Sciences**

Chiang Mai  
Romane Chaiwarith, MD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$25,240<sup>1</sup>

Tavitiya Sudjaritruk, MD, ScM  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$15,000<sup>3</sup>

Bone health and vitamin D status among perinatally HIV-infected Asian children with virological suppression  
\$72,092<sup>5</sup>

#### **Chiangrai Prachanukroh Hospital**

Chiang Rai  
Rawiwan Hansudewechakul, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$15,000<sup>3</sup>

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI  
\$4,650<sup>1</sup>

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia  
\$63,613<sup>2</sup>

Pacharee Kantipong, MD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$15,460<sup>1</sup>

[HIV-NAT / Thai Red Cross AIDS Research Centre](#)  
Bangkok  
Praphan Phanuphak, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$22,890<sup>1</sup>

Examining the prevalence rate and determinants of frailty in the HIV positive and negative Thai populations  
\$30,873<sup>1</sup>

Torsak Bunupuradah, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$15,000<sup>1</sup>

Bone health and vitamin D status among perinatally HIV-infected Asian children with virological suppression  
\$110,282<sup>5</sup>

Changes in metabolic and inflammatory markers in HIV-positive adolescents using hormonal contraception  
\$10,350<sup>3</sup>

Promoting Mental Health Interventions for Perinatally HIV-Infected Thai Youth: Expanded Scope  
\$6,500<sup>3</sup>

Stephen Kerr, PhD  
Prospective validation of an adherence monitoring tool among HIV-infected children and adolescents at leDEA sites  
\$10,814<sup>1</sup>

Nittaya Phanuphak, MD, PhD  
Identifying Biomarkers of Anal Intraepithelial Neoplasia in Thai MSM  
\$95,000<sup>1</sup>

Study on anal HPV infection and anal intraepithelial neoplasia among MSM in Indonesia, Malaysia, and Thailand  
\$34,646<sup>1</sup> \$172,602<sup>3</sup>

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia (central lab & data manager)  
\$249,357<sup>2</sup>

HIV-HPV Research in Asia and the Pacific Meeting  
\$20,619<sup>1</sup>

Wasana Prasitsuebsai, MD, MPH  
Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI  
\$5,775<sup>1</sup>

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI (data mgmt center)  
\$8,000<sup>1</sup>

Study Site: Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia  
\$80,223<sup>2</sup>

Coordinating Center: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children  
\$46,467<sup>1</sup>

TASER-Px: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children  
\$13,000<sup>5</sup>

Kiat Ruxrunghtham, MD  
Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment  
\$48,412

[Thai Red Cross AIDS Research Centre](#)  
Bangkok

Nittaya Phanuphak, MD, PhD  
Strengthening skills and qualifications of HRA clinicians in the Asia-Pacific region  
\$42,600

eHealth interventions to improve treatment adherence and retention in care among HIV-positive young Thai MSM  
\$44,993<sup>5</sup>

[Mahidol University Faculty of Medicine, Siriraj Hospital](#)

Bangkok  
Kulkanya Chokephaibulkit, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$15,000<sup>3</sup>

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI  
\$7,236<sup>1</sup>

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia  
\$66,216<sup>2</sup>

[Ramathibodi Hospital, Mahidol University](#)  
Bangkok

Sasisopin Kiartiburanakul, MD, MHS  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,880<sup>1</sup>

[Srinagarind Hospital, Khon Kaen University](#)

Khon Kaen  
Pagakrong Lumbiganon, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$15,000<sup>3</sup>

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI  
\$5,150<sup>1</sup>

## VIETNAM

[Bach Mai Hospital](#)

Hanoi  
Pham Thi Thanh Thuy, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,070<sup>1</sup>

[Children's Hospital 1](#)

Ho Chi Minh City  
Truong Huu Khanh, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$25,000<sup>3</sup>

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI  
\$8,500<sup>1</sup>

TASER-Px: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children  
\$14,000<sup>3</sup>

Thoa Kim Le Phan, MD  
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia  
\$9,548<sup>2</sup>

[Children's Hospital 2](#)

Ho Chi Minh City  
Do Chau Viet, MD  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$20,000<sup>3</sup>

TASER-Px: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children  
\$20,000<sup>3</sup>

[Hung Vuong Hospital](#)

Ho Chi Minh City  
Dang Le Dung Hanh, MD, MA  
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia  
\$15,598<sup>2</sup>

[National Hospital of Pediatrics](#)

Hanoi  
Nguyen Van Lam, MD, MSc  
TREAT Asia Pediatric HIV Observational Database (TApHOD)  
\$20,000<sup>3</sup>

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI  
\$4,200<sup>1</sup>

TASER-Px: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children  
\$8,500<sup>3</sup>

[National Hospital of Tropical Diseases](#)

Hanoi  
Nguyen Van Kinh, MD, PhD  
TREAT Asia HIV Observational Database (TAHOD) including NCD Data  
\$23,230<sup>1</sup>

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment  
\$32,065

[Vietnam Network of People Living with HIV \(VNP+\)](#)

Hanoi  
Do Dang Dong  
Strengthen advocacy on HCV Diagnosis, Care and Treatment  
\$2,000<sup>4</sup>

## 2015 GMT INITIATIVE GRANTS AND AWARDS

All projects listed below were awarded amfAR funding for the period October 1, 2014, through September 30, 2015.

### GMT IMPLEMENTATION SCIENCE RESEARCH GRANTS

#### Continuum of Care Innovations for GMT in Burma/Myanmar

Principal Investigator: Chris Beyrer, MD, MPH  
Johns Hopkins University  
Baltimore, MD  
\$899,887

#### Gender-Affirmative Transgender Care to Improve the HIV Treatment Cascade

Principal Investigator: Javier Lama, MD, MPH  
Asociación Civil Impacta Salud y Educación  
Lima, Peru  
\$876,684

#### Innovative strategy to offer online Test and Treat services for Thai MSM

Principal Investigator: Nittaya Phanuphak, MD, PhD  
Thai Red Cross AIDS Research Centre  
Bangkok, Thailand  
\$900,000

### GLOBAL LUBRICANT ACCESS MOBILIZATION AWARDS

#### GLAM: CNET

Project Director: Stephen Diaz  
Collaborative Network of Persons Living with HIV (C-NET+)  
Belize City, Belize  
\$5,000

#### GLAM: ALFIL

Project Director: Ricardo Erazo  
Asociación ALFIL  
Quito, Ecuador  
\$5,000

#### GLAM: Grupo Genesis Panama Positivo

Project Director: Israel Ned Gill Smith  
Grupo Génesis Panamá Positivo (GGP+)  
Panamá, Panamá  
\$5,000

#### GLAM: Red Trebol

Project Director: Pamela Valenzuela  
Mesa De Trabajo Nacional  
Cochabamba, Bolivia  
\$5,000

### GENERAL GMT INITIATIVE GRANTS AND AWARDS

#### Opposites Attract Study (Extension)

Principal Investigator: Andrew Grulich, PhD, FAFPM, DRACOG  
University of New South Wales  
Sydney, Australia  
\$212,340

#### Opposites Attract Study Site

Site Principal Investigator:  
Beatriz Grinsztejn, MD, PhD  
Fiotec - Foundation for Scientific and Technological Development in Health, Instituto de Pesquisa Clinica Evandro Chagas  
Rio de Janeiro, Brazil  
\$96,398

#### A Training Program for HIV Research among MSM in Developing World Settings

Project Director: Ronald D. Stall, PhD, MPH  
University of Pittsburgh  
Pittsburgh, PA  
\$163,804

## 2015 PUBLIC POLICY AWARDS

The projects listed below were awarded during the period October 1, 2014, through September 30, 2015.

<sup>1</sup>Funded with support from the Open Society Foundations

<sup>2</sup>Funded with support from the MAC AIDS Fund

### UNITED STATES

#### Implementation of Electronic Medical Record System

Project Director: Ron Simmons, PhD  
Us Helping Us - People Into Living, Inc.  
Washington, DC  
\$4,875

#### Harm Reduction Services and Overdose

Prevention Advocacy in Puerto Rico  
Project Director: Rafael Torruella, PhD  
Intercambios Puerto Rico  
Fajardo, Puerto Rico  
\$20,000<sup>1</sup>

### INTERNATIONAL

#### Meaningful Engagement of People who Use Drugs (PUD) in Removing Legal Barriers towards access to antiretroviral treatment

Project Director: Edo Agustian  
Persaudaraan Korban Napza Indonesia (PKNI)  
Jakarta, Indonesia  
\$20,000<sup>1</sup>

#### Advocating for Human rights and access to health services for People Who Use Drugs (PWUD)

Project Director: Happy Leonard Assan  
Tanzania network for people who use drugs  
Dar-es-salaam, Tanzania  
\$10,000<sup>1</sup>

#### Project ACE

Project Director: Shaun Shelly  
TB/HIV Care Association  
Cape Town, South Africa  
\$19,466<sup>1</sup>

#### Qualitative Assessment of Budget Development and the Improvement of Health Outcomes

Project Director: Nhlanhla Ndlovu  
Centre for Economic Governance and AIDS in Africa  
Howick, South Africa  
\$39,945<sup>2</sup>

## 2015 COMMUNITY OUTREACH AWARDS

#### Andrea Bocelli Foundation-St. Damien Pediatric Hospital, Haiti

Charities Aid Foundation of America  
Alexandria, VA USA  
\$301,163

#### The Learning Resource

Museum of AIDS in Africa  
Johannesburg, Gauteng South Africa  
\$25,000



## Financial Highlights




For the year ended September 30, 2015


<b>Public Support and Revenue</b>		
Public support	\$	7,142,007
Special events		24,033,779
Planned giving		5,095,713
Government funding		10,220,999
Investment income and other revenue		117,700
<b>Total public support and revenue</b>	<b>\$</b>	<b>46,610,198</b>
<hr/>		
<b>Expenses</b>		
Research	\$	15,282,648
TREAT Asia		5,820,593
GMT Initiative		2,365,247
Public Policy		2,045,870
Public Information		4,259,732
<b>Total program services</b>	<b>\$</b>	<b>29,774,090</b>
<hr/>		
Fundraising		5,653,227
Management and general		2,454,606
<b>Total supporting services</b>	<b>\$</b>	<b>8,107,833</b>
<hr/>		
<b>Total expenses</b>	<b>\$</b>	<b>37,881,923</b>
<hr/>		
Change in net assets		8,728,275
Net assets, beginning of year		44,310,347
<b>Net assets, end of year</b>	<b>\$</b>	<b>53,038,622</b>

## Statement of Financial Position






<b>Assets</b>		
Cash and investments	\$	58,377,633
Accounts receivable, net		7,557,420
Prepaid expenses and other assets		3,027,106
Fixed assets, net		2,288,934
<b>Total Assets</b>	<b>\$</b>	<b>71,251,093</b>
<hr/>		
<b>Liabilities</b>		
Accounts payable and accrued expenses	\$	3,435,700
Grants and fellowships payable, net		3,049,552
Deferred support and refundable advances		10,067,061
Other long-term liabilities		1,660,158
<b>Total liabilities</b>	<b>\$</b>	<b>18,212,471</b>
<hr/>		
<b>Total net assets</b>		<b>53,038,622</b>
<hr/>		
<b>Total liabilities and net assets</b>	<b>\$</b>	<b>71,251,093</b>


## Expenses

	Fundraising	\$	5,653,227
	Management and general		2,454,606
	Program		29,774,090
<b>Total</b>		<b>\$</b>	<b>37,881,923</b>



## Program Expenses

	Research	\$	15,282,648
	TREAT Asia		5,820,593
	GMT Initiative		2,365,247
	Public Policy		2,045,870
	Public Information		4,259,732
<b>Total</b>		<b>\$</b>	<b>29,774,090</b>





## BOARD OF TRUSTEES

Fiscal year 2015

Chairman of the Board

**Kenneth Cole**

Chairman  
Kenneth Cole Productions  
New York, NY

Founding Chairman

**Mathilde Krim, Ph.D.**

Adjunct Professor  
Mailman School of Public Health  
Columbia University  
New York, NY

Vice Chairman

**Patricia J. Matson**

Senior Vice President, Communications (ret.)  
ABC, Inc.  
New York, NY

Vice Chairman

**John C. Simons**

Managing Partner  
Corporate Fuel Partners, LLC  
New York, NY

Treasurer

**Wallace Sheft, C.P.A.**

Partner (ret.)  
Sheft & Co.  
Westbury, NY

Secretary

**Mervyn F. Silverman, M.D., M.P.H.**

President  
Mervyn F. Silverman Associates  
Crockett, CA

### TRUSTEES

**Arlen H. Andelson**

Andelson Properties  
Los Angeles, CA

**Harry Belafonte**

President  
Belafonte Enterprises, Inc.  
New York, NY

**David Bohnett**

Chairman  
David Bohnett Foundation  
Beverly Hills, CA

**Zev Braun**

President and CEO  
Braun Entertainment Group, Inc.  
Beverly Hills, CA

**Jonathan S. Canno**

New York, NY

**Donald A. Capoccia**

Managing Principal  
BFC Partners  
Brooklyn, NY

**R. Martin Chavez, Ph.D.**

Chief Information Officer  
The Goldman Sachs Group, Inc.  
New York, NY

**Jane B. Eisner**

President  
The Eisner Foundation  
Bel Air, CA

**T. Ryan Greenawalt**

Managing Director  
Ramirez & Co.  
President  
Harrison Street Productions  
New York, NY

**Regan Hofmann**

Policy Officer  
Washington Liaison Office  
UNAIDS  
Washington, D.C.

**Michael J. Klingensmith**

CEO and Publisher  
Minneapolis Star Tribune  
Minneapolis, MN

**Kevin McClatchy**

Chairman of the Board  
The McClatchy Company  
Ligonier, PA

**Michele V. McNeill, Pharm.D.**

Chairman  
McNeill Family Foundation  
Sarasota, FL

**Edward L. Milstein**

Co-Chairman  
Milstein Brothers and Capital Partners  
New York, NY

**Cindy D. Rachofsky**

Philanthropist  
Dallas, TX

**Vincent A. Roberti**

Chairman, Roberti Global  
Washington, D.C.

**Bill Roedy**

London, UK

**Raymond F. Schinazi, Ph.D., D.Sc.**

Frances Winship Walters Professor  
Director, Laboratory of Biochemical Pharmacology  
Emory University  
Decatur, GA

**Alan D. Schwartz**

Executive Chairman  
Guggenheim Partners, LLC  
New York, NY

**Diana L. Taylor**

Vice Chair  
Solera Capital, LLC  
New York, NY

### TRUSTEE EMERITUS

**Arthur J. Ammann, M.D.**

President, Global Strategies for HIV Prevention  
Clinical Professor of Pediatrics  
University of California, San Francisco  
San Francisco, CA

### IN MEMORIAM

**Dame Elizabeth Taylor**

Founding International Chairman

**Sheldon W. Andelson, Esq.**

Arnold W. Klein, M.D.  
Mrs. Albert D. Lasker  
Jonathan M. Mann, M.D., M.P.H.  
Maxine Mesinger  
Pauline Phillips  
Natasha Richardson  
Allan Rosenfield, M.D.  
Peter Scott, Esq.  
Tom Stoddard  
Joel D. Weisman, D.O.

### SPECIAL APPOINTMENTS

Global Campaign Chair

Sharon Stone

Global Fundraising Chairman

Milutin Gatsby

### amfAR AMBASSADORS

Cheyenne Jackson

Janet Jackson

Milla Jovovich

Liza Minnelli

Michelle Yeoh

### COMMITTEES OF THE BOARD OF TRUSTEES

#### Executive

Kenneth Cole, Chair  
Michael J. Klingensmith  
Mathilde Krim, Ph.D.  
Patricia J. Matson  
Vincent A. Roberti  
Wallace Sheft, C.P.A.  
Mervyn F. Silverman, M.D., M.P.H.  
John C. Simons

#### Audit

Wallace Sheft, C.P.A., Chair  
R. Martin Chavez, Ph.D.  
John C. Simons

#### Board Development

Donald A. Capoccia, Co-Chair  
Patricia J. Matson, Co-Chair  
Arlen Andelson  
Bill Roedy  
Mervyn F. Silverman, M.D., M.P.H.

#### Communications/Social Media/Marketing

Regan Hofmann, Chair  
Kenneth Cole  
T. Ryan Greenawalt  
Patricia J. Matson  
Kevin McClatchy  
Vincent A. Roberti  
Bill Roedy

#### Compensation and Organizational Development

John C. Simons, Chair  
Michael J. Klingensmith  
Kevin McClatchy

#### Finance & Budget

Michael J. Klingensmith, Chair  
Vincent A. Roberti  
John C. Simons

#### Fund Development

Vincent A. Roberti, Chair  
Arlen Andelson  
Jonathan S. Canno  
Donald A. Capoccia  
T. Ryan Greenawalt  
Cindy Rachofsky  
Raymond F. Schinazi, Ph.D., D.Sc.

#### Investment

Michael J. Klingensmith, Chair  
R. Martin Chavez, Ph.D.  
Edward L. Milstein  
Vincent A. Roberti  
Wallace Sheft, C.P.A.  
John C. Simons

## SCIENTIFIC ADVISORY COMMITTEE

**Daniel C. Douek, M.D., Ph.D. (Chair)**  
Chief, Human Immunology Section  
Vaccine Research Center  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health

**Galit Alter, Ph.D.**  
Associate Professor  
Department of Medicine  
Harvard Medical School

**Deborah Anderson, Ph.D.**  
Professor of Obstetrics/Gynecology and Microbiology  
Boston University School of Medicine

**Jintanat Ananworanich, M.D., Ph.D.**  
Associate Director for Therapeutics Research  
U.S. Military HIV Research Program

**Warren A. Andiman, M.D.**  
Professor Emeritus of Pediatrics  
Co-Director, Yale Adoption Clinic  
Medical Director, Pediatric AIDS Care Program  
Yale School of Medicine

**Eric Arts, Ph.D.**  
Professor  
Department of Microbiology and Immunology  
The University of Western Ontario

**Livio Azzoni, Ph.D.**  
Senior Staff Scientist  
The Wistar Institute  
Philadelphia, PA

**Michael Betts, Ph.D.**  
Associate Professor  
Department of Microbiology  
Perelman School of Medicine  
University of Pennsylvania

**Jason Brechley, Ph.D.**  
Senior Investigator  
Immunopathogenesis Section  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health

**Dennis R. Burton, Ph.D.**  
Professor  
Department of Immunology  
The Scripps Research Institute

**Salvatore T. Butera, D.V.M., Ph.D.**  
Chief Science Officer  
Scripps CHAVI-ID  
The Scripps Research Institute

**Edward Campbell, Ph.D.**  
Assistant Professor  
Department of Microbiology and Immunology  
School of Medicine  
Loyola University at Chicago

**Alex Carballo-Dieguez, Ph.D.**  
Co-Director and Senior Research Scientist  
HIV Center for Clinical and Behavioral Studies  
New York State Psychiatric Institute  
Columbia University

**Nicolas Chomont, Ph.D.**  
Assistant Professor  
Microbiology and Immunology  
Université de Montréal, Centre de Recherche du CHUM

**David B. Clifford, M.D.**  
Professor  
Department of Neurology  
Washington University School of Medicine

**C. Budd Colby, Ph.D.**  
Principal  
Colby Biomedical Ventures

**Grant Colfax, M.D.**  
Director  
Marin Health and Human Services  
San Rafael, California

**Elizabeth Connick, M.D.**  
Professor of Medicine  
Chief, Division of Infectious Diseases  
Department of Medicine  
University of Arizona

**Deborah Jean Cotton, M.D., M.P.H.**  
Professor of Medicine  
Boston University School of Medicine

**Bryan R. Cullen, Ph.D., D.Sc.**  
James B. Duke Professor  
Department of Molecular Genetics and Microbiology  
Director, Duke University Center for Virology  
Duke University Medical Center

**Susanna Cunningham-Rundles, Ph.D.**  
Professor Emerita of Research Immunology  
Department of Pediatrics  
Weill Cornell Medical College

**Richard Thomas D'Aquila, M.D.**  
The Howard Taylor Ricketts Professor of Medicine  
Division of Infectious Diseases  
Director, Northwestern HIV Translational Research Center  
Feinberg School of Medicine  
Northwestern University

**Steven Deeks, M.D.**  
Professor  
Department of Medicine  
University of California, San Francisco

**Sherry Deren, Ph.D.**  
Co-Director  
Center for Drug Use and HIV Research  
New York University College of Nursing

**Roger Detels, M.D., M.S.**  
Professor of Epidemiology  
School of Public Health  
University of California, Los Angeles

**Carl W. Dieffenbach, Ph.D.**  
Director  
Division of AIDS (DAIDS)  
National Institute of Allergy and Infectious Diseases  
National Institutes of Health

**D. Peter Drotman, M.D., M.P.H.**  
Editor in-Chief  
Emerging Infectious Diseases  
Centers for Disease Control and Prevention

**Anke A. Ehrhardt, Ph.D.**  
Director  
Division of Gender, Sexuality, & Health  
Program for the Study of LGBT Health  
NYS Psychiatric Institute/Columbia University

**Jacob Estes, Ph.D.**  
Principal Scientist/Principal Investigator  
AIDS and Cancer Virus Program (ACVP)  
Frederick National Laboratory for Cancer Research  
National Cancer Institute

**Homayoon Farzadegan, Ph.D.**  
Professor  
Department of Epidemiology  
Johns Hopkins Bloomberg School of Public Health

**Dianne M. Finkelstein, Ph.D.**  
Professor of Biostatistics  
Harvard School of Public Health  
Director of the Cancer Center Biostatistics  
Massachusetts General Hospital

**Gerald Herbert Friedland, M.D.**  
Professor and Director  
AIDS Care Program  
Department of Internal Medicine  
Yale School of Medicine

**Rémi Fromentin, Pharm.D., Ph.D.**  
Postdoctoral Researcher  
Université de Montréal, Centre de Recherche du CHUM

**Howard E. Gendelman, M.D.**  
Professor and Chair, Department of Pharmacology and Experimental Neuroscience  
Margaret R. Larson Professor of Internal Medicine and Infectious Diseases  
Director, Center for Neurodegenerative Disorders  
University of Nebraska Medical Center

**Nancy L. Haigwood, Ph.D.**  
Director and Senior Scientist  
Division of Pathobiology and Immunology  
Oregon National Primate Research Center  
Oregon Health and Science University

**Timothy Henrich, M.D.**  
Assistant Professor of Medicine  
Division of Infectious Disease  
University of California, San Francisco

**Charles H. Hinkin, Ph.D.**  
Professor  
Department of Psychiatry and Biobehavioral Sciences  
David Geffen School of Medicine  
University of California, Los Angeles

**David Ho, M.D.**  
Scientific Director, Chief Executive Officer  
Aaron Diamond AIDS Research Center

**Thomas J. Hope, Ph.D.**  
Professor  
Department of Cell and Molecular Biology  
Feinberg School of Medicine  
Northwestern University

**Shiu-Lok Hu, Ph.D.**  
Professor  
School of Pharmacy  
University of Washington

**Jonathan Karn, Ph.D.**  
Director  
Center for AIDS Research  
Case Western Reserve University

**Vineet KewalRamani, Ph.D.**  
Chief, Model Development Section  
HIV Drug Resistance Program  
National Cancer Institute  
National Institutes of Health

**Hans-Peter Kiem, M.D., F.A.C.P.**  
Full Member, Clinical Research Division  
Jose Carreras/E. Donnall Thomas Endowed  
Chair for Cancer Research  
Fred Hutchinson Cancer Research Center  
Seattle, WA

**Scott Kitchen, Ph.D.**  
Assistant Professor of Medicine  
Division of Hematology and Oncology  
David Geffen School of Medicine  
University of California, Los Angeles

**Richard Kornbluth, M.D., Ph.D.**  
President and Chief Scientific Officer  
Multimeric Biotherapeutics, Inc.

**Richard A. Koup, M.D.**  
Deputy Director, Vaccine Research Center  
Chief, Immunology Laboratory  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

**Nathaniel R. Landau, Ph.D.**  
Professor  
Department of Microbiology  
New York University School of Medicine

**Alan L. Landay, Ph.D.**  
Professor and Chairman  
Department of Immunology and Microbiology  
Rush-Presbyterian-St. Luke's Medical Center

**Michael Lederman, M.D.**  
Scott R. Inkle Professor of Medicine  
Associate Director, Center for AIDS Research  
Case Western Reserve University

**Tun-Hou Lee, D.Sc.**  
Professor of Virology, Emeritus  
Department of Immunology and Infectious  
Diseases  
Harvard School of Public Health

**Michael J. Leibowitz, M.D., Ph.D.**  
Professor, Medical Microbiology and Immunology  
University of California, Davis

**Robert J. Levine, M.D.**  
Professor of Medicine  
Center for Interdisciplinary Research on AIDS  
Yale University

**Sharon Lewin, FRACP, Ph.D.**  
Director  
Peter Doherty Institute for Infection and Immunity  
University of Melbourne

**Mathias Lichterfeld, M.D.**  
Assistant Professor of Medicine  
Massachusetts General Hospital

**Judy Lieberman, M.D., Ph.D.**  
Senior Investigator  
Immune Disease Institute  
Professor of Pediatrics  
Harvard Medical School

**H. Kim Lyerly, M.D.**  
Professor in Surgery, Immunology, Pathology  
George Barth Geller Chair of Cancer Research  
Director of the Center of Applied Therapeutics  
Duke Cancer Institute  
Duke University Medical Center

**Frank Maldarelli, M.D., Ph.D.**  
Investigator  
HIV DRP Host-Virus Interaction Branch  
National Cancer Institute  
National Institutes of Health

**David M. Margolis, M.D.**  
Professor of Medicine, Microbiology and  
Immunology, and Epidemiology  
School of Medicine  
University of North Carolina at Chapel Hill

**Martin H. Markowitz, M.D.**  
Professor and Clinical Director  
Aaron Diamond AIDS Research Center

**Kenneth Hugh Mayer, M.D.**  
Infectious Disease Attending & Director of HIV  
Prevention Research  
Beth Israel Deaconess Medical Center

Professor of Medicine  
Harvard Medical School

Medical Research Director, Co-Chair  
The Fenway Institute/Fenway Health

**Joseph M. McCune, M.D., Ph.D.**  
Professor of Medicine  
Chief, Division of Experimental Medicine  
University of California, San Francisco

**Donna Mildvan, M.D.**  
Chief, Division of Infectious Diseases  
Department of Medicine  
Beth Israel Medical Center

**Jay A. Nelson, Ph.D.**  
Professor and Director  
Vaccine and Gene Therapy Institute  
Oregon Health and Science University

**Una O'Doherty, M.D., Ph.D.**  
Associate Professor  
Department of Pathology and Laboratory Medicine  
Perelman School of Medicine  
University of Pennsylvania

**Nancy Padian, Ph.D., M.P.H.**  
Adjunct Professor of Epidemiology  
School of Public Health  
University of California, Berkeley

**Savita Pahwa, M.D.**  
Professor of Microbiology and Immunology  
Professor in Pediatrics and Medicine  
Director of the Miami Center for AIDS Research  
University of Miami Leonard M. Miller School of  
Medicine

**Tristram G. Parslow, M.D., Ph.D.**  
William Patterson Timmie Professor and Chair  
Department of Pathology and Laboratory Medicine  
Emory University School of Medicine

**Matija Peterlin, M.D.**  
Professor of Medicine, Microbiology and  
Immunology  
Department of Medicine  
University of California, San Francisco

**Lynn Pulliam, Ph.D.**  
Professor  
Department of Laboratory Medicine and Medicine  
University of California, San Francisco  
Veterans Affairs Medical Center

**Lee Ratner, M.D., Ph.D.**  
Professor  
Department of Medicine  
Washington University School of Medicine

**Andrew Rice, Ph.D.**  
Professor  
Department of Molecular Virology and  
Microbiology  
Baylor College of Medicine

**Charles Rinaldo, Ph.D.**  
Professor and Chair  
Infectious Diseases and Microbiology  
University of Pittsburgh

**Melissa Robbiani, Ph.D.**  
Senior Scientist and Director of Biomedical HIV  
Research  
Center for Biomedical Research  
Population Council

**Ruth M. Ruprecht, M.D., Ph.D.**  
Scientist, Department of Virology and Immunology  
Southwest National Primate Research Center  
Director, Texas Biomed AIDS Research Program  
Texas Biomedical Research Institute

**Sarah Schlesinger, M.D.**  
Associate Professor of Clinical Investigation  
Laboratory of Molecular Immunology  
The Rockefeller University

**Frederick A. Schmitt, Ph.D.**  
Professor  
Departments of Neurology, Psychiatry, and  
Psychology and Behavioral Science  
Sanders Brown Center on Aging  
University of Kentucky

**Gerald Schochetman, Ph.D.**  
Senior Director, Diagnostics Research  
Abbott Laboratories

**Robert Turner Schooley, M.D.**  
Academic Vice Chair  
Professor and Head  
Department of Medicine/Division of Infectious  
Diseases  
University of California, San Diego

**Gail Skowron, M.D.**  
Professor of Medicine  
Boston University School of Medicine

**Serena Spudich, M.D., M.A.**  
Associate Professor of Neurology  
Division Chief, Neurological Infections  
and Global Neurology  
Department of Neurology  
Yale School of Medicine

**Leonidas Stamatatos, Ph.D.**  
Member  
Fred Hutchinson Cancer Research Center  
Vaccine and Infectious Disease Division  
Immunology and Vaccine Development Program  
Seattle, WA

**Mario Stevenson, Ph.D.**  
Professor of Medicine  
Chief, Division of Infectious Diseases  
University of Miami Leonard M. Miller School  
of Medicine

**Susana Valente, Ph.D.**  
Associate Professor  
Department of Immunology and Microbial  
Sciences  
The Scripps Research Institute

**Barbara Visscher, M.D., Dr.P.H.**  
Professor of Epidemiology  
University of California, Los Angeles

**David Vlahov PhD, RN**  
Professor of Nursing,  
Epidemiology, and Biostatistics  
University of California, San Francisco

**David J. Volsky, Ph.D.**  
Professor of Medicine and Pathology  
Icahn School of Medicine at Mt. Sinai

Director of Molecular Virology Laboratory  
Department of Medicine  
Mount Sinai St. Luke's and Roosevelt Hospitals

**Steven S. Witkin, Ph.D.**  
Professor of Immunology  
Department of Obstetrics and Gynecology  
Weill Cornell Medical College

**Peter R. Wolfe, M.D.**  
Associate Clinical Professor  
David Geffen School of Medicine  
University of California, Los Angeles

**Steven Wolinsky, M.D.**  
Professor  
Medicine/Infectious Diseases  
Feinberg School of Medicine  
Northwestern University

**Richard T. Wyatt, Ph.D.**  
Professor of Immunology  
IAVI Center for Neutralizing Antibodies  
The Scripps Research Institute

**Jerome Zack, Ph.D.**  
Professor  
Department of Medicine  
David Geffen School of Medicine  
University of California, Los Angeles

## PROGRAM ADVISORY COUNCIL

**Mervyn F. Silverman, M.D., M.P.H. (Chairman)**  
President  
Mervyn F. Silverman Associates  
Crockett, CA

**Judith D. Auerbach, Ph.D.**  
Science and Policy Consultant and Professor  
School of Medicine  
University of California, San Francisco

**David Bloom, Ph.D.**  
Clarence James Gamble Professor of Economics  
and Demography  
Department of Global Health and Population  
Harvard School of Public Health  
Boston, MA

**Tim Brown, Ph.D.**  
Senior Fellow  
The East-West Center  
Honolulu, HI

**Daniel Douek, M.D., Ph.D.**  
Chief, Human Immunology Section  
Vaccine Research Center  
National Institute of Allergy and Infectious  
Diseases  
National Institutes of Health

**Daria J. Hazuda, Ph.D.**  
Vice President, Scientific Affairs for Infectious  
Disease  
Merck & Company, Inc.  
West Point, PA

**Kenneth Hugh Mayer, M.D.**  
Infectious Disease Attending & Director of HIV  
Prevention Research  
Beth Israel Deaconess Medical Center

Professor of Medicine  
Harvard Medical School

Medical Research Director, Co-Chair  
The Fenway Institute/Fenway Health

**Mario Stevenson, Ph.D.**  
Professor of Medicine  
Chief, Division of Infectious Diseases  
University of Miami Leonard M. Miller School of  
Medicine

**Jeffrey L. Sturchio, Ph.D.**  
Senior Partner  
Rabin Martin  
New York, NY

Visiting Scholar  
The Institute for Applied Economics, Global Health  
and the Study of Business Enterprise  
Johns Hopkins University

Member  
The Council on Foreign Relations  
Washington, D.C.

**Phill Wilson**  
Chief Executive Officer and President  
The Black AIDS Institute  
Los Angeles, CA

## MANAGEMENT GROUP

**Kevin Robert Frost**  
Chief Executive Officer

**Anthony Ancona**  
Vice President and Director, Human Resources

**Susan J. Blumenthal, M.D., M.P.A.**  
Senior Policy and Medical Advisor

**Bradley Jensen**  
Chief Financial Officer

**Rowena Johnston, Ph.D.**  
Vice President and Director, Research

**Jeffrey Laurence, M.D.**  
Senior Scientific Consultant for Programs

**John F. Logan, Ph.D., J.D.**  
Vice President and General Counsel

**Gregorio Millett, M.P.H.**  
Vice President and Director, Public Policy

**Eric Muscatell**  
Vice President, Development

**AnnMari Shannahan**  
Vice President, Public Information

**Annette Sohn, M.D.**  
Vice President and Director, TREAT Asia

**amfAR, The Foundation for AIDS Research**

**NEW YORK**

120 Wall Street, 13th Floor  
New York, NY 10005-3908  
(212) 806-1600 (tel)  
(212) 806-1601 (fax)

**WASHINGTON, D.C.**

1100 Vermont Avenue, NW  
Suite 600  
Washington, DC 20005  
(202) 331-8600 (tel)  
(202) 331-8606 (fax)

**BANGKOK, THAILAND**

TREAT Asia  
Exchange Tower  
388 Sukhumvit Road, Suite 2104  
Klongtoey, Bangkok 10110  
Thailand  
+66 (0)2 663 7561 (tel)  
+66 (0)2 663 7562 (fax)

**[www.amfar.org](http://www.amfar.org)**



[bbb.org/charity](http://bbb.org/charity)

amfAR meets the BBB  
Wise Giving Alliance's  
Standards for Charity  
Accountability.



★★★★  
**CHARITY NAVIGATOR**  
Four Star Charity